139 related articles for article (PubMed ID: 22362285)
1. Molecular targeting therapy against promyelocytic leukemia protein using arsenic acids in experimental intracranial medulloblastoma.
Gu C; Yokota N; Gao Y; Amano S; Koizumi S; Tokuyama T; Namba H
Neurol Med Chir (Tokyo); 2012; 52(2):62-7. PubMed ID: 22362285
[TBL] [Abstract][Full Text] [Related]
2. Arsenic trioxide and promyelocytic leukemia protein-adenovirus synergistically inhibit in vitro and in vivo growth of a hepatoma cell line.
Cui L; Zhang S; Zhang W; Hu Z; Cao Z; Li T
Oncol Res; 2010; 18(7):305-14. PubMed ID: 20377131
[TBL] [Abstract][Full Text] [Related]
3. Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth.
Zhou W; Cheng L; Shi Y; Ke SQ; Huang Z; Fang X; Chu CW; Xie Q; Bian XW; Rich JN; Bao S
Oncotarget; 2015 Nov; 6(35):37300-15. PubMed ID: 26510911
[TBL] [Abstract][Full Text] [Related]
4. PML targeting eradicates quiescent leukaemia-initiating cells.
Ito K; Bernardi R; Morotti A; Matsuoka S; Saglio G; Ikeda Y; Rosenblatt J; Avigan DE; Teruya-Feldstein J; Pandolfi PP
Nature; 2008 Jun; 453(7198):1072-8. PubMed ID: 18469801
[TBL] [Abstract][Full Text] [Related]
5. Nuclear matrix associated protein PML: an arsenic trioxide apoptosis therapeutic target protein in HepG2 cells.
Yu D; Wang Z; Zhu L; Chew EC
Chin Med J (Engl); 2003 Jan; 116(1):93-8. PubMed ID: 12667397
[TBL] [Abstract][Full Text] [Related]
6. Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation.
Wang QQ; Zhou XY; Zhang YF; Bu N; Zhou J; Cao FL; Naranmandura H
Oncotarget; 2015 Sep; 6(28):25646-59. PubMed ID: 26213848
[TBL] [Abstract][Full Text] [Related]
7. Epstein - Barr virus Latent Membrane Protein 1 suppresses reporter activity through modulation of promyelocytic leukemia protein-nuclear bodies.
Sides MD; Block GJ; Chadwick RW; Shan B; Flemington EK; Lasky JA
Virol J; 2011 Oct; 8():461. PubMed ID: 21975125
[TBL] [Abstract][Full Text] [Related]
8. A new era for an ancient drug: arsenic trioxide and Hedgehog signaling.
Beauchamp EM; Uren A
Vitam Horm; 2012; 88():333-54. PubMed ID: 22391311
[TBL] [Abstract][Full Text] [Related]
9. Triptolide inhibits the proliferation and migration of medulloblastoma Daoy cells by upregulation of microRNA-138.
Zhang H; Li H; Liu Z; Ge A; Guo E; Liu S; Chen Z
J Cell Biochem; 2018 Dec; 119(12):9866-9877. PubMed ID: 30156009
[TBL] [Abstract][Full Text] [Related]
10. Sumoylation of the Tumor Suppressor Promyelocytic Leukemia Protein Regulates Arsenic Trioxide-Induced Collagen Synthesis in Osteoblasts.
Xu WX; Liu SZ; Wu D; Qiao GF; Yan J
Cell Physiol Biochem; 2015; 37(4):1581-91. PubMed ID: 26517826
[TBL] [Abstract][Full Text] [Related]
11. Importance of ERK activation in As2O3-induced differentiation and promyelocytic leukemia nuclear bodies formation in neuroblastoma cells.
Petit A; Delaune A; Falluel-Morel A; Goullé JP; Vannier JP; Dubus I; Vasse M
Pharmacol Res; 2013 Nov; 77():11-21. PubMed ID: 24004656
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis.
Hayakawa F; Privalsky ML
Cancer Cell; 2004 Apr; 5(4):389-401. PubMed ID: 15093545
[TBL] [Abstract][Full Text] [Related]
13. Death by arsenic: implications of PML sumoylation.
Mann KK; Miller WH
Cancer Cell; 2004 Apr; 5(4):307-9. PubMed ID: 15093537
[TBL] [Abstract][Full Text] [Related]
14. The role of PML in hematopoietic and leukemic stem cell maintenance.
Nakahara F; Weiss CN; Ito K
Int J Hematol; 2014 Jul; 100(1):18-26. PubMed ID: 24488785
[TBL] [Abstract][Full Text] [Related]
15. PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies.
Iwanami A; Gini B; Zanca C; Matsutani T; Assuncao A; Nael A; Dang J; Yang H; Zhu S; Kohyama J; Kitabayashi I; Cavenee WK; Cloughesy TF; Furnari FB; Nakamura M; Toyama Y; Okano H; Mischel PS
Proc Natl Acad Sci U S A; 2013 Mar; 110(11):4339-44. PubMed ID: 23440206
[TBL] [Abstract][Full Text] [Related]
16. Mutant p53 protein is targeted by arsenic for degradation and plays a role in arsenic-mediated growth suppression.
Yan W; Zhang Y; Zhang J; Liu S; Cho SJ; Chen X
J Biol Chem; 2011 May; 286(20):17478-86. PubMed ID: 21454520
[TBL] [Abstract][Full Text] [Related]
17. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.
Zhang XW; Yan XJ; Zhou ZR; Yang FF; Wu ZY; Sun HB; Liang WX; Song AX; Lallemand-Breitenbach V; Jeanne M; Zhang QY; Yang HY; Huang QH; Zhou GB; Tong JH; Zhang Y; Wu JH; Hu HY; de Thé H; Chen SJ; Chen Z
Science; 2010 Apr; 328(5975):240-3. PubMed ID: 20378816
[TBL] [Abstract][Full Text] [Related]
18. SUMO deconjugation is required for arsenic-triggered ubiquitylation of PML.
Fasci D; Anania VG; Lill JR; Salvesen GS
Sci Signal; 2015 Jun; 8(380):ra56. PubMed ID: 26060329
[TBL] [Abstract][Full Text] [Related]
19. Arsenic mediated disruption of promyelocytic leukemia protein nuclear bodies induces ganciclovir susceptibility in Epstein-Barr positive epithelial cells.
Sides MD; Block GJ; Shan B; Esteves KC; Lin Z; Flemington EK; Lasky JA
Virology; 2011 Jul; 416(1-2):86-97. PubMed ID: 21605886
[TBL] [Abstract][Full Text] [Related]
20. Promyelocytic leukemia protein induces arsenic trioxide resistance through regulation of aldehyde dehydrogenase 3 family member A1 in hepatocellular carcinoma.
Zhang X; Yang XR; Sun C; Hu B; Sun YF; Huang XW; Wang Z; He YF; Zeng HY; Qiu SJ; Cao Y; Fan J; Zhou J
Cancer Lett; 2015 Sep; 366(1):112-22. PubMed ID: 26118777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
